AMIH Subsidiary, Legend Nutrition, Inc., Executes Asset Purchase Agreement to Acquire Assets of Nutritional Supplement Retail Store
12 nov. 2019 19h30 HE
|
American International Holdings Corp.
ADDISON, TX, Nov. 12, 2019 (GLOBE NEWSWIRE) -- American International Holdings Corp. (OTC: AMIH, or the “Company”) is pleased to announce that its newly formed subsidiary, Legend Nutrition, Inc....
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
22 juil. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with...
FibroGen Reports Third Quarter 2018 Financial Results
08 nov. 2018 16h02 HE
|
FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
12 sept. 2018 09h30 HE
|
FibroGen, Inc
SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
21 mai 2018 16h00 HE
|
FibroGen, Inc
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that updated results from the company’s randomized, double-blind,...
FibroGen Reports First Quarter 2018 Financial Results
09 mai 2018 16h02 HE
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
05 sept. 2017 16h05 HE
|
FibroGen, Inc.
SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
14 août 2017 16h05 HE
|
aTyr Pharma Inc.
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
07 août 2017 16h50 HE
|
FibroGen, Inc.
Meets Primary Endpoint with Statistical Significance Management to discuss results on today’s quarterly financial results conference call SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- FibroGen,...